



# SCOOPS 2023 en oncologie

Pr Mathieu LARAMAS

Oncologue Médical

CHU Grenoble Alpes





# Team Mission Impossible

- Pr Julie Charles
- Dr Emmanuelle Jacquet
- Dr Lysiane Molina
- Dr Gaël Roth
- Pr Anne Claire Toffart



# Immunothérapie néo-adjuvante dans le mélanome IIB à IVC

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

## Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

S.P. Patel, M. Othus, Y. Chen, G.P. Wright, Jr., K.J. Yost, J.R. Hyingstrom,  
N ENGL J MED 388;9 NEJM.ORG MARCH 2, 2023

Pembro 3 cycles NA + Pembro 15 cycles en adjuvant  
vs pembro adjuvant

Survie sans évènement à 2 ans : 72% vs 49%



# Sein

## The NEW ENGLAND JOURNAL of MEDICINE


ESTABLISHED IN 1812

JULY 7, 2022

VOL. 387 NO. 1

**Her2 faible : 60% des tumeurs !**

### Trastuzumab Deruxtecan vs Physician's Choice in Hormone Receptor-Positive Cohort



#### No. at Risk

Trastuzumab deruxtecan	331	325	323	319	314	309	303	293	285	280	268	260	250	228	199	190	168	144	116	95	81	70	51	40	26	14	9	8	6	6	2	1	1	1	0
Physician's choice	163	151	145	143	139	135	130	124	115	109	104	98	96	89	80	71	56	45	37	29	25	23	16	14	7	5	3	1	0						

# Sein




The **NEW ENGLAND**  
JOURNAL of **MEDICINE**

ESTABLISHED IN 1812

JULY 7, 2022

VOL. 387 NO. 1

**Her2 faible : 60% des tumeurs !**



# Gynécologie : immunothérapie dans le pelvis !

- Carcinome de l'endomètre métastatique
  - Dostarlimab + Pacli-Carbo – 1<sup>ère</sup> ligne (Ruby<sup>1</sup>) – accès précoce
    - A 24 mois, PFS HR 0.64, p<0,001 / OS HR 0.64, p<0,001
  - Pembrolizumab Paclitaxel Carboplatine – 1<sup>ère</sup> ligne (KeyNote 868<sup>2</sup>)
    - pMMR PFS 13.1 vs 8.7 (HR 0.54, p<0,001) – dMMR PFS 12 mois 74% vs 30% - HR 0.30, p<0.001)
  - Lenvatinib pembrolizumab (KeyNote 775<sup>3</sup>) – ≥2<sup>ème</sup> ligne
    - PFS 7.2 vs 3.8 (HR 0.56, p<0,001) / OS 18.3 vs 11.4 (HR 0.62, p<0,001)
- Cancer du col utérin : pembrolizumab paclitaxel carboplatine (KeyNote 826<sup>4</sup>)
  - OS 26.4 vs 16.8, p<0,0001

1. M.R. Mirza et al. N Engl J Med 2023; 388:2145-2158
2. R.N. Eskander et al. N Engl J Med 2023; 388:2159-2170
3. V. Makker et al. N Engl J Med 2022; 386:437-448
4. B. Monk et al. #5500; ASCO 2023






# Hématologie : extens bispécifiques (et trisp)


blinatumomab (CD19xCD3)  
NVG-111 (ROR-1xCD3)




AFM13 (CD30xCD16)




GTB-3650 (CD16xIL-15xCD33)




HPN217 (BCMAxHSAxCD3)




glofitamab (CD20xCD3)  
alnuctamab (BCMAxCD3)  
forimtamig (GPC5DXCD3)




mosunetuzumab (CD20xCD3)




epcoritamab (CD20xCD3)  
talquetamab (GPC5DXCD3)  
teclistamab (BCMAxCD3)  
elranatamab (BCMAxCD3)




odronextamab (CD20xCD3)  
linvoseltamab (BCMAxCD3)




plamotamab (CD20xCD3)  
ISB1342, Y150 (CD38xCD3)




TNB-486 (CD19xCD3)




Abbv-383 (BCMAxCD3)




englumafusp alfa (CD19x4-1BBL)




EMB-06 (BCMAxCD3)




SAR443579 (CD123xNKp46)




APVO436 (CD123xCD3)




MGD024 (CD123xCD3)



AFM28 (CD123xCD16)  
CLN-049 (FLT3xCD3)  
ATG-101 (PD-L1x4-1BB)



SAR442257 (CD38xCD3xCD28)



JNJ-80948543 (CD79BxCD20xCD3)

# Hématologie : extension du domaine des bispécifiques (et trispécifiques...)

Drug name	Format	Specificity	Indication	Clinical trial	Phase	Sponsor
Blinatumomab	BiTE	CD19/CD3	ALL	NCT02013167	Marketed 2014	Amgen
Mosunetuzumab (RG7828, CD20-TDB)	Hz IgG1-based, Fc -silent, KIH	CD20/CD3	FL	NCT02500407	Marketed 2022	Genentech-Roche
Epcoritamab (GEN3013)	Hz/hu IgG1-based Duobody	CD20/CD3	DLBCL	NCT03625037	Marketed 2023	Genmab-Abbvie
Glofitamab (RO7082859, RG6026)	Hz IgG1-based 2 + 1 CrossMab	CD20/CD3	DLBCL	NCT03075696	Marketed 2023	Roche
Odronextamab (REGN1979)	Hu IgG4-based, VelociBi	CD20/CD3	NHL	NCT03888105	2 (potentially pivotal)	Regeneron
Teclistamab (JNJ 7957)	Hz IgG4 Duobody	BCMA/CD3	MM	NCT04557098	Marketed 2022	Janssen
Elranatamab (PF-06863135)	Hz IgG2, hinge-mutation	BCMA/CD3	MM	NCT05020236	In review	Pfizer
Linvoseltamab (REGN5458)	IgG4 VelociBi	BCMA/CD3	MM	NCT03761108	2 (potentially pivotal)	Regeneron
Talquetamab (JNJ 7564)	Hz IgG4 Duobody	GPRC5D/CD3	MM	NCT04634552	In review	Janssen

Data obtained from: The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or US (Last access: July 2023); [www.antibodysociety.org/resources/approved-antibodies](http://www.antibodysociety.org/resources/approved-antibodies); ClinicalTrials.gov (last access: July 2023); and web pages of sponsors (last access: July 2023)

Tapia-Galisteo *et al.*

*Journal of Hematology & Oncology* (2023) 16:83

<https://doi.org/10.1186/s13045-023-01482-w>


30 novembre 2023

CENTRE DES CONGRES D'AIX LES BAINS




# Digestif : cancer oeso-gastriques métastatiques

## Her2 - : GASTFOX – TFOX vs FOLFOX



Zaanan et al. #LBA77 – ESMO 2023

## Her2+++ : KeyNote-811 - trastu + CT +/- pembro




Janjigian et al. – The Lancet - Published Online October 20, 2023 [https://doi.org/10.1016/S0140-6736\(23\)02033-0](https://doi.org/10.1016/S0140-6736(23)02033-0)

# Oncologie thoracique


- ADAURA<sup>1</sup> : osimertinib en adjuvant dans les NSCLC EGFR muté – bénéfique en survie globale

- HR OS = 0.49 (0.34-0.70, p<0.001)




- ALINA<sup>2</sup> : alectinib en adjuvant dans les NSCLC ALK muté/réarrangé

- HR DFS = 0.24 (0.13-0.43, p<0.001)



- CheckMate 816<sup>3</sup> : accès précoce NIVOLUMAB en péri-opératoire



1. M. Tsuboi et al. N Engl J Med 2023; 389:137-147.
2. B. Salomon et al. #LBA2 – ESMO 2023
3. PM Forde et al. N Engl J Med 2022; 386:1973-1985




# THE SCOOP of the soops 2023 en oncologie



# Cancer de vessie métastatique

## EV-302/KEYNOTE-A39 (NCT04223856)



Powles et al. #LBA6 – ESMO 2023



# Cancer de vessie métastatique

## EV-302/KEYNO

### Patient population

- Previously untreated la/mUC
- Eligible for platinum, EV, and P
- PD-(L)1 inhibitor naïve
- GFR  $\geq 30$  mL/min<sup>a</sup>
- ECOG PS  $\leq 2^b$

N=88

## Overall Survival

Risk of death was reduced by 53% in patients who received EV+P

